Rationale for Polyclonal Intravenous Immunoglobulin Adjunctive Therapy in COVID-19 Patients: Report of a Structured Multidisciplinary Consensus.

Irene ColorettiGiorgio BerlotStefano BusaniFrancesco Giuseppe De Rosa Abele DonatiFrancesco ForforiGiacomo GrasselliLucia MirabellaCarlo TasciniPierluigi VialeMassimo Girardis

Published in: Journal of clinical medicine (2021)

As with other immunotherapies, IVIg adjunctive therapy may have a potential role in the management of COVID-19 patients. The ongoing trials will clarify the appropriate target population and the true effectiveness.

Keyphrases

sars cov
randomized controlled trial
systematic review
clinical trial
high dose
low dose
bone marrow
mesenchymal stem cells
clinical practice